Loading company…
Sophia Genetics SA provides a cloud-based analytics platform for oncology and rare disease patients, listed on NASDAQ.
Based in Saint Sulpice, Switzerland, and founded in 2011, Sophia Genetics SA provides the cloud-based Sophia DDM platform for patients with oncology and rare diseases. The platform uses machine learning and pattern recognition to characterize genomic variants and connect patients to clinical trials. In October 2020, the company raised USD 110 million in Series F funding co-led by aMoon and Hitachi Ventures. In July 2021, it raised USD 234 million in an IPO at USD 18 per share on NASDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in